BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 15836863)

  • 1. A random effects model for multistate survival analysis with application to bone marrow transplants.
    Bhattacharyya M; Klein JP
    Math Biosci; 2005 Mar; 194(1):37-48. PubMed ID: 15836863
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multi-state models and outcome prediction in bone marrow transplantation.
    Keiding N; Klein JP; Horowitz MM
    Stat Med; 2001 Jun; 20(12):1871-85. PubMed ID: 11406847
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Allogeneic hematopoietic stem cell transplantation in patients with chronic myeloid leukemia in the Czech Republic--a retrospective analysis of results in years 1988-2005].
    Faber E; Koza V; Vítek A; Mayer J; Sedlácek P; Zák P; Zapletalová J; Benesová K; Krejcová H; Steinerová K; Maresová I; Cetkovský P
    Vnitr Lek; 2006 Dec; 52(12):1172-80. PubMed ID: 17299910
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effects and prognostic factors of HLA-matched sibling donor allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia].
    Tong XZ; Li J; Tan EX; Zhang GC; Wu XY; Peng AH; Zheng D; Zou WY; Hong WD; Luo SK
    Zhonghua Zhong Liu Za Zhi; 2006 Jul; 28(7):545-8. PubMed ID: 17147125
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Laryngeal stenosis associated with chronic graft-versus-host disease following unrelated bone marrow transplantation.
    Hirokawa M; Kume M; Wu T; Ishikawa K; Sawada KI
    Bone Marrow Transplant; 2006 Sep; 38(5):387-8. PubMed ID: 16862163
    [No Abstract]   [Full Text] [Related]  

  • 6. Resolution of atopic dermatitis following allogeneic bone marrow transplantation for chronic myelogenous leukemia.
    Koharazawa H; Kanamori H; Takabayashi M; Yamaji S; Taguchi J; Fujimaki K; Ishigatsubo Y
    Bone Marrow Transplant; 2005 Jun; 35(12):1223-4. PubMed ID: 15880131
    [No Abstract]   [Full Text] [Related]  

  • 7. HLA-mismatched/haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for chronic myeloid leukemia: improved outcomes in patients in accelerated phase and blast crisis phase.
    Xiao-Jun H; Lan-Ping X; Kai-Yan L; Dai-Hong L; Huan C; Wei H; Yu-Hong C; Jing-Zhi W; Yao C; Xiao-Hui Z; Hong-Xia S; Dao-Pei L
    Ann Med; 2008; 40(6):444-55. PubMed ID: 18608121
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduced rank proportional hazards model for competing risks.
    Fiocco M; Putter H; Van Houwelingen JC
    Biostatistics; 2005 Jul; 6(3):465-78. PubMed ID: 15831577
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A semi-Markov model for multistate and interval-censored data with multiple terminal events. Application in renal transplantation.
    Foucher Y; Giral M; Soulillou JP; Daures JP
    Stat Med; 2007 Dec; 26(30):5381-93. PubMed ID: 17987670
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association with the presence of naive T cells in chronic myeloid leukemia patients after allogeneic human stem cell transplantation and the lower incidence of chronic graft-versus host disease and relapse.
    Wysoczanska B; Bogunia-Kubik K; Dlubek D; Jaskula E; Sok A; Drabczak-Skrzypek D; Sedzimirska M; Lange A
    Transplant Proc; 2007 Nov; 39(9):2898-901. PubMed ID: 18022011
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relative survival multistate Markov model.
    Huszti E; Abrahamowicz M; Alioum A; Binquet C; Quantin C
    Stat Med; 2012 Feb; 31(3):269-86. PubMed ID: 22052528
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Composite vascularized skin/bone transplantation models for bone marrow-based tolerance studies.
    Ozmen S; Ulusal BG; Ulusal AE; Izycki D; Siemionow M
    Ann Plast Surg; 2006 Mar; 56(3):295-300. PubMed ID: 16508361
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-efficacy of imatinib versus allogeneic bone marrow transplantation with a matched unrelated donor in the treatment of chronic myelogenous leukemia: a decision-analytic approach.
    Skrepnek GH; Ballard EE
    Pharmacotherapy; 2005 Mar; 25(3):325-34. PubMed ID: 15843279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Filgrastim-mobilized peripheral blood progenitor cells versus bone marrow transplantation for treating leukemia: 3-year results from the EBMT randomized trial.
    Schmitz N; Beksac M; Bacigalupo A; Ruutu T; Nagler A; Gluckman E; Russell N; Apperley J; Szerm J; Bradstock K; Buzyn A; Schlegelberger B; Matcham J; Gratwohl A
    Haematologica; 2005 May; 90(5):643-8. PubMed ID: 15921379
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Allogeneic haematopoietic cell transplantation for chronic myelogenous leukaemia in the era of imatinib: a retrospective multicentre study.
    Bornhäuser M; Kröger N; Schwerdtfeger R; Schafer-Eckart K; Sayer HG; Scheid C; Stelljes M; Kienast J; Mundhenk P; Fruehauf S; Kiehl MG; Wandt H; Theuser C; Ehninger G; Zander AR;
    Eur J Haematol; 2006 Jan; 76(1):9-17. PubMed ID: 16343266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Squamous cell carcinoma of the tongue after bone marrow transplant and graft-versus-host disease: a case report and review of the literature.
    Byun JH; Park BW; Kim JR; Lee GW; Lee JH
    J Oral Maxillofac Surg; 2008 Jan; 66(1):144-7. PubMed ID: 18083430
    [No Abstract]   [Full Text] [Related]  

  • 17. Autoantibody-mediated agranulocytosis in association with chronic GVHD.
    Ruck S; Hilgendorf I; Müller-Hilke B; Kiefel V; Junghanss C; Freund M; Greinix H; Wolff D
    Bone Marrow Transplant; 2008 Sep; 42(5):359-60. PubMed ID: 18574447
    [No Abstract]   [Full Text] [Related]  

  • 18. Acute severe form of lichenoid graft-versus-host disease after donor lymphocyte infusions.
    Ruiz-Genao DP; F-Peñas P; Daudén E; García-F-Villalta MJ; Fraga J; García-Diez A
    J Eur Acad Dermatol Venereol; 2006 May; 20(5):632-4. PubMed ID: 16684312
    [No Abstract]   [Full Text] [Related]  

  • 19. [Second transplant from the same donor without conditioning for bone marrow aplasia after non-myeloablative hematopoietic stem cell transplantation for chronic myeloid leukemia].
    Ishikawa I; Miyamura K; Yamada M; Sasaki O; Harigae H; Kameoka J; Meguro K; Sasaki T
    Rinsho Ketsueki; 2005 Dec; 46(12):1288-92. PubMed ID: 16447801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Late mortality and relapse following BuCy2 and HLA-identical sibling marrow transplantation for chronic myelogenous leukemia.
    Copelan EA; Crilley PA; Szer J; Dodds AJ; Stevenson D; Phillips G; Elder P; Nivison-Smith I; Avalos BR; Penza S; Topolsky D; Sobecks R; Kalaycio M; Bolwell BJ
    Biol Blood Marrow Transplant; 2009 Jul; 15(7):851-5. PubMed ID: 19539217
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.